NCT05503329 is a clinical trial of arterial lactate level in STEMI, sponsored by Ahmed Maher Teaching Hospital.

Who is sponsoring NCT05503329?

NCT05503329 is sponsored by Ahmed Maher Teaching Hospital.

What drugs are being tested in NCT05503329?

Interventions in NCT05503329: arterial lactate level.

Is NCT05503329 still recruiting?

NCT05503329 is currently completed. Last updated 18 August 2022.

Last reviewed 2022-08-18 · How we verify

NCT05503329

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostic Value of Lactate Levels in Patients With STEMI Undergoing Primary PCI

Completed Last updated 18 August 2022

What this trial tests

trial testing arterial lactate level in STEMI in 300 participants. Completed in 30 June 2022.

Timeline

25 January 2022

Primary endpoint
27 June 2022

30 June 2022

Quick facts

Lead sponsor	Ahmed Maher Teaching Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	300
Start date	25 January 2022
Primary completion	27 June 2022
Estimated completion	30 June 2022
Sites	1 location across Egypt

Drugs / interventions tested

arterial lactate level

Conditions studied

STEMI — all drugs for STEMI →

Sponsor

Ahmed Maher Teaching Hospital

Who can join

18 and older, any sex, with STEMI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the prognostic value of systemic arterial lactate levels in patients with ST segment elevation myocardial infarction undergoing primary PCI and correlate with the results of primary PCI and 30 days MACE follow up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for STEMI

Currently open trials in the same condition.

NCT06966674 — No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track · NA · recruiting
NCT06678074 — Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI · Phase 1, PHASE2 · active not recruiting
NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
NCT06528821 — AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS · active not recruiting
NCT07026708 — TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevat · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05503329 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ahmed Maher Teaching Hospital
Last refreshed: 18 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05503329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing